Exogenus was the only Portuguese company selected to pitch at the European Innovation Council’s Investor Day on Health on May 18th and 19th to present its pioneering technology to leading Life Sciences investors from across the globe, featuring its Series A investment round, to bring its innovative exosome-based therapy into the clinical setting!
Exogenus lead product Exo-101 is derived from Umbilical Cord Blood, and has proven anti-inflammatory and regenerative properties, demonstrated in many different preclinical models, including wound healing, psoriasis and lung inflammation.
The company selected Acute Respiratory Distress Syndrome (ARDS) as the first lead indication for Exo-101, a common cause of death in COVID-19 patients and several other infectious and non-infectious diseases, with no available treatment. Exogenus aims to conclude IND-enabling preclinical studies and move into a Phase 1/2a FIH clinical trial based on an accelerated roadmap of 24 months.
Led by CEO Joana Simões Correia, a key opinion leader in the exosome space, Exogenus is currently looking for Series A funding to demonstrate that Exo-101 can be lifesaving in ARDS, providing a tool for future pandemics, while also preparing for the use of the drug in other inflammatory diseases thanks to its unique multifactorial Mode-of-Action (MOA).